SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful launch of its BlueBird-6 satellite, a critical milestone signifying the company's transition toward commercial scalability for direct-to-device broadband. The community is buzzing with excitement, anticipating significant future growth and contract announcements, though some express caution regarding valuation and a potential "sell the news" reaction. This event firmly positions ASTS as a major player in the rapidly evolving space-based cellular network industry.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new all-time highs. This rally is fueled by tightening global supply due to upcoming Chinese export restrictions, alongside booming industrial demand from EV batteries, solar, and AI data centers. The community is actively discussing a potential 'silver squeeze' and a significant re-rating of silver's value, though some anticipate a near-term pullback after its rapid ascent.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is a major talking point with significant anticipation surrounding its upcoming showcases of commercial quantum computing solutions at industry events. The community is deeply divided, with many optimistic about the company's potential for broad adoption and future partnerships, while a vocal segment expresses caution regarding valuation and recent executive stock sales. This reflects broader market debate on the commercial readiness and investment risks within the evolving quantum computing sector.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is currently trending following its announced inclusion in the S&P MidCap 400 index, a move expected to generate significant institutional buying pressure and boost market visibility. The community is actively discussing this catalyst as a major inflection point for the pure-play automation leader, anticipating strong long-term growth driven by its Agentic AI solutions and robust financial position. Many investors see this as a key moment, despite some discussions around short-term profit-taking.

Starfighters Space Inc

Starfighters Space Inc. (FJET), a recently public aerospace company, is trending due to extreme volatility driven by its low float and very high short interest. The community is fiercely divided, with many anticipating a significant short squeeze while others label it a pump-and-dump. There is widespread discussion about alleged market manipulation influencing its price action amidst this speculative fervor.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is trending on widespread anticipation for the FDA's decision on Narsoplimab, a first-in-class drug for TA-TMA, with many speculating on an early approval before the December 26th PDUFA date. The community is actively discussing potential for a significant price surge fueled by high unmet medical need, strong trial data, and the recent $2.1 billion Novo Nordisk deal that has bolstered Omeros's financial position. This binary event has triggered intense debate over short manipulation and a possible "shakeout" of shares ahead of what many believe will be a transformative approval.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending as Sanofi moves to acquire the company for $15.50 per share in a $2.2 billion deal, significantly expanding Sanofi's vaccine pipeline with DVAX's hepatitis B vaccine and developing shingles treatment. The community is celebrating the premium offered, while also speculating on the strategic value Sanofi may see in DVAX's recent licensing of an oral COVID-19 vaccine program. This acquisition has sparked broader conversations about potential interest in smaller biotech companies within the sector.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is trending due to significant insider share accumulation by its CEO, fueling speculation and high retail interest in this low-float Hong Kong-based company. The community is actively debating its extreme volatility and whether it can replicate past parabolic runs seen in similar small-cap plays, despite ongoing discussions about its valuation and business model.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending as gold reaches new all-time highs, driven by persistent central bank buying, geopolitical tensions, and expectations of future monetary easing. The community is actively debating whether this reflects a sustainable "currency reset" or a speculative rally, with many viewing it as an essential safe-haven asset amid global economic uncertainties. Discussions also highlight gold's strong performance compared to other assets like Bitcoin, underscoring its perceived value in a changing financial landscape.

Utopia is a digital paradise designed to reward every step of a user's journey. It is a world where community and cutting-edge technology converge to foster unprecedented freedom, creativity, and tangible value.At the heart of Utopia lies a living, breathing ecosystem where user engagement directly fuels the economy.Participants guide the Utopia girl on her path, drawing her closer to the world's core. With each step, a user's influence grows, as do their potential BNB rewards. Utopia is built on the principle that exploration and active participation should be directly linked to prosperity.The path is for each user to shape, and every discovery brings them closer to the center of it all.

Utopia

Utopia Crypto is trending as its recent listing on a major exchange has sparked widespread bullish sentiment within the community. Investors are actively discussing its potential as a "hidden gem" and future powerhouse, driven by its platform focused on in-game token rewards and ongoing development. The strong conviction points to anticipated significant growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data

Nektar Therapeutics stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin.read more...

What is HC Wainwright's Estimate for NKTR FY2027 Earnings?

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Stock analysts at HC Wainwright issued their FY2027 EPS estimates for shares of Nektar Therapeutics in a research report issued on Tuesday, December...

Nektar Therapeutics (NASDAQ:NKTR) Shares Down 6.5% - Should You Sell?

Nektar Therapeutics (NASDAQ:NKTR) Stock Price Down 6.5% - Should You Sell...

BTIG Research Issues Positive Forecast for Nektar Therapeutics (NASDAQ:NKTR) Stock Price

BTIG Research raised their target price on shares of Nektar Therapeutics from $100.00 to $118.00 and gave the stock a "buy" rating in a report on Tuesday...

Nektar Therapeutics (NASDAQ:NKTR) Given New $135.00 Price Target at HC Wainwright

HC Wainwright lifted their price objective on Nektar Therapeutics from $120.00 to $135.00 and gave the stock a "buy" rating in a research note on Tuesday...

Nektar Therapeutics (NASDAQ:NKTR) Shares Gap Down - Should You Sell?

Nektar Therapeutics (NASDAQ:NKTR) Shares Gap Down - Should You Sell...

Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion

Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before eligibility adjustments.read more...

Nektar Therapeutics Sees Unusually Large Options Volume (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Investors purchased 3,883 call options on the company. This represents an...

REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata

REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes...

Nektar Therapeutics (NASDAQ:NKTR) Stock Price Up 11% - Here's Why

Nektar Therapeutics (NASDAQ:NKTR) Shares Up 11% - Time to Buy...

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

NKTR
Nektar Therapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NKTR News

NKTRNektar Therapeutics